

Meeting Report | Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Stockholm, Sweden, June 26–27, 2012

Psoriasis Outcome Measures: A Report from the GRAPPA 2012 Annual Meeting

Alice B. Gottlieb and April W. Armstrong

The Journal of Rheumatology August 2013, 40 (8) 1428-1433; DOI: <https://doi.org/10.3899/jrheum.130456>

[Article](#)[Figures & Data](#)[References](#)[Info & Metrics](#)[PDF](#)[eLetters](#)[← Previous](#)[Next →](#)

Abstract

Psoriasis is a multisystem disease. The cutaneous and musculoskeletal manifestations (psoriatic arthritis) are well recognized. However, the other manifestations of psoriatic disease including metabolic syndrome, atherosclerotic cardiovascular disease, depression, poor self-esteem, and self-destructive habits including obesity, smoking and excess alcohol consumption are underappreciated. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members addressed the need to develop uniform, validated, standardized outcome measures for psoriatic disease, measures that are useful to all stakeholders including patients, physicians, regulators, and payers.

Key Indexing Terms:

[PSORIATIC DISEASE](#)[PSORIASIS](#)[OMERACT](#)[NATIONAL PSORIASIS FOUNDATION](#)[COMORBIDITIES](#)

Footnotes

- Supported in part by a grant from the Advancing Innovation in Dermatology Foundation.